Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Ovarian Cancer Immunotherapy

  • Silvia von Mensdorff-Pouilly
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6954-3

Definition

Despite advances in chemotherapeutic regimens, ovarian cancer has a poor prognosis, and its most frequent type, epithelial ovarian cancer, is the leading cause of death from gynecological malignancies. Immunotherapy, which endeavors to direct the host’s own immune system against antigens expressed by tumor cells to create an immune response that will destroy the established tumor or eliminate micrometastases still present after primary treatment, may contribute toward improving ovarian cancer prognosis. The induced immune response may lead to a state of immune surveillance that will eliminate tumor cells as they arise, preventing recurrence of disease. Contrary to other epithelial cancers, such as colorectal cancer and breast cancer, there still are no approved immunotherapeutic strategies for the treatment of ovarian cancer. Approaches that are being tested in clinical trials include the administration of monoclonal antibodies (MAbs; Monoclonal Antibody Therapy),...

Keywords

Vascular Endothelial Growth Factor Ovarian Cancer Epithelial Ovarian Cancer Ovarian Cancer Patient Folate Receptor Alpha 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. DeLeo AB, Whiteside TL (2008) Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines 7(7):1031–1040CrossRefPubMedPubMedCentralGoogle Scholar
  2. Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388–1397CrossRefPubMedPubMedCentralGoogle Scholar
  3. Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K, Nijman HW (2014) Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev 1:CD007287Google Scholar
  4. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373:1033–1040CrossRefPubMedPubMedCentralGoogle Scholar

See Also

  1. (2012) Adjuvant. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 75. doi:10.1007/978-3-642-16483-5_107Google Scholar
  2. (2012) Allogeneic. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 138. doi:10.1007/978-3-642-16483-5_194Google Scholar
  3. (2012) Antigen-Presenting Cells. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 209–210. doi:10.1007/978-3-642-16483-5_321Google Scholar
  4. (2012) Autoimmunity. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 312. doi:10.1007/978-3-642-16483-5_478Google Scholar
  5. (2012) Avastin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 323. doi:10.1007/978-3-642-16483-5_6577Google Scholar
  6. (2012) BCG. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 356. doi:10.1007/978-3-642-16483-5_560Google Scholar
  7. (2012) CA125. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 577–578. doi:10.1007/978-3-642-16483-5_761Google Scholar
  8. (2012) Cancer Testis Antigens. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 630. doi:10.1007/978-3-642-16483-5_817Google Scholar
  9. (2012) Carboplatin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 641. doi:10.1007/978-3-642-16483-5_833Google Scholar
  10. (2012) CD8+ Cytotoxic T-Cells. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 703. doi:10.1007/978-3-642-16483-5_918Google Scholar
  11. (2012) DETOX. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1101. doi:10.1007/978-3-642-16483-5_6652Google Scholar
  12. (2012) EGFR. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1211. doi:10.1007/978-3-642-16483-5_1828Google Scholar
  13. (2012) Epithelial Ovarian Cancer. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1292. doi:10.1007/978-3-642-16483-5_6952Google Scholar
  14. (2012) Folate Receptor Alpha. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1440. doi:10.1007/978-3-642-16483-5_6960Google Scholar
  15. (2012) Granulocyte-Macrophage Colony-Stimulating Factor. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1597. doi:10.1007/978-3-642-16483-5_6778Google Scholar
  16. (2012) Helper T Cells. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 1639–1640. doi:10.1007/978-3-642-16483-5_2609Google Scholar
  17. (2012) Idiotype. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1804. doi:10.1007/978-3-642-16483-5_2944Google Scholar
  18. (2012) Immunosuppression. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1831. doi:10.1007/978-3-642-16483-5_3012Google Scholar
  19. (2012) Interferon Gamma. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1888. doi:10.1007/978-3-642-16483-5_3092Google Scholar
  20. (2012) MAGE. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2135. doi:10.1007/978-3-642-16483-5_6375Google Scholar
  21. (2012) Major Histocompatibility Complex. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2137. doi:10.1007/978-3-642-16483-5_3500Google Scholar
  22. (2012) Monoclonal Antibody Therapy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 2367–2368. doi:10.1007/978-3-642-16483-5_3823Google Scholar
  23. (2012) MUC1. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 2384–2386. doi:10.1007/978-3-642-16483-5_3870Google Scholar
  24. (2012) Neoangiogenesis. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2473. doi:10.1007/978-3-642-16483-5_4006Google Scholar
  25. (2012) Opsonization. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2643. doi:10.1007/978-3-642-16483-5_4244Google Scholar
  26. (2012) P53. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2747. doi:10.1007/978-3-642-16483-5_4331Google Scholar
  27. (2012) Phagocytosis. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2840. doi:10.1007/978-3-642-16483-5_4493Google Scholar
  28. (2012) Tolerance. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3723. doi:10.1007/978-3-642-16483-5_5853Google Scholar
  29. (2012) Tumor-Associated Antigen. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 3807–3808. doi:10.1007/978-3-642-16483-5_6017Google Scholar
  30. (2012) Tumor Suppressor. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3803. doi:10.1007/978-3-642-16483-5_6056Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyVrije Universiteit Medisch Centrum (VUmc)AmsterdamThe Netherlands